<DOC>
	<DOCNO>NCT00948818</DOCNO>
	<brief_summary>The objective trial determine efficacy safety linaclotide administer patient irritable bowel syndrome constipation ( IBS-C ) . The primary efficacy parameter percentage patient treatment group meet protocol definition Abdominal Pain Complete Spontaneous Bowel Movement ( APC ) Responder .</brief_summary>
	<brief_title>Trial Linaclotide Administered Patients With Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patient meet protocol criterion IBS : report abdominal discomfort pain two follow three feature : 1 . Relieved defecation 2 . Onset associate change frequency stool 3 . Onset associate change form ( appearance ) stool Patient report &lt; 3 bowel movement ( BMs ) per week ( absence laxative , suppository , enema use precede 24 hour ) report strain , lumpy hard stool , and/or sensation incomplete evacuation &gt; 25 % BMs Patient successfully complete protocol procedure ( clinically significant finding ) : physical exam , 12lead ECG , clinical laboratory test ( patient may require colonoscopy per American Gastroenterological Association ( AGA ) guideline ) Patient compliant Interactive Voice Response System ( IVRS ) daily diary reporting BM habit IBS symptom Patient history loose watery stool &gt; 25 % BMs Patient structural abnormality gastrointestinal ( GI ) tract history disease condition affect GI motility Patient protocolexcluded clinically significant medical surgical history concomitant medication use could confound study assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Constipation</keyword>
	<keyword>Linaclotide</keyword>
</DOC>